» Articles » PMID: 23545254

Knockdown of HMGA1 Inhibits Human Breast Cancer Cell Growth and Metastasis in Immunodeficient Mice

Overview
Publisher Elsevier
Specialty Biochemistry
Date 2013 Apr 3
PMID 23545254
Citations 18
Authors
Affiliations
Soon will be listed here.
Abstract

The high mobility group A1 gene (HMGA1) has been previously implicated in breast carcinogenesis, and is considered an attractive target for therapeutic intervention because its expression is virtually absent in normal adult tissue. Other studies have shown that knockdown of HMGA1 reduces the tumorigenic potential of breast cancer cells in vitro. Therefore, we sought to determine if silencing HMGA1 can affect breast cancer development and metastatic progression in vivo. We silenced HMGA1 expression in the human breast cancer cell line MDA-MB-231 using an RNA interference vector, and observed a significant reduction in anchorage-independent growth and tumorsphere formation, which respectively indicate loss of tumorigenesis and self-renewal ability. Moreover, silencing HMGA1 significantly impaired xenograft growth in immunodeficient mice, and while control cells metastasized extensively to the lungs and lymph nodes, HMGA1-silenced cells generated only a few small metastases. Thus, our results show that interfering with HMGA1 expression reduces the tumorigenic and metastatic potential of breast cancer cells in vivo, and lend further support to investigations into targeting HMGA1 as a potential treatment for breast cancer.

Citing Articles

Breast Cancer: Circular RNAs Mediating Efficacy in Preclinical Models.

Weidle U, Hsia H, Brinkmann U Cancer Genomics Proteomics. 2023; 20(3):222-238.

PMID: 37093684 PMC: 10148070. DOI: 10.21873/cgp.20377.


The anticancer effects of Metformin in the male germ tumor SEM-1 cell line are mediated by HMGA1.

Salatino A, Mirabelli M, Chiefari E, Greco M, Di Vito A, Bonapace G Front Endocrinol (Lausanne). 2022; 13:1051988.

PMID: 36506071 PMC: 9727077. DOI: 10.3389/fendo.2022.1051988.


High-Mobility Group AT-Hook 1 Served as a Prognosis Biomarker and Associated with Immune Infiltrate in Hepatocellular Carcinoma.

Wei Y, Yang C, Wei Z, Liao X, He Y, Zhou X Int J Gen Med. 2022; 15:609-621.

PMID: 35058711 PMC: 8765458. DOI: 10.2147/IJGM.S344858.


tRNA Queuosine Modification Enzyme Modulates the Growth and Microbiome Recruitment to Breast Tumors.

Zhang J, Lu R, Zhang Y, Matuszek Z, Zhang W, Xia Y Cancers (Basel). 2020; 12(3).

PMID: 32182756 PMC: 7139606. DOI: 10.3390/cancers12030628.


HMGA Genes and Proteins in Development and Evolution.

Vignali R, Marracci S Int J Mol Sci. 2020; 21(2).

PMID: 31963852 PMC: 7013770. DOI: 10.3390/ijms21020654.


References
1.
Flohr A, Rogalla P, Bonk U, Puettmann B, Buerger H, Gohla G . High mobility group protein HMGA1 expression in breast cancer reveals a positive correlation with tumour grade. Histol Histopathol. 2003; 18(4):999-1004. DOI: 10.14670/HH-18.999. View

2.
Reeves R, Beckerbauer L . HMGI/Y proteins: flexible regulators of transcription and chromatin structure. Biochim Biophys Acta. 2001; 1519(1-2):13-29. DOI: 10.1016/s0167-4781(01)00215-9. View

3.
Chiappetta G, Tallini G, De Biasio M, Manfioletti G, Martinez-Tello F, Pentimalli F . Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res. 1998; 58(18):4193-8. View

4.
Hristov A, Cope L, Di Cello F, Reyes M, Singh M, Hillion J . HMGA1 correlates with advanced tumor grade and decreased survival in pancreatic ductal adenocarcinoma. Mod Pathol. 2009; 23(1):98-104. PMC: 3092591. DOI: 10.1038/modpathol.2009.139. View

5.
Xu Y, Sumter T, Bhattacharya R, Tesfaye A, Fuchs E, Wood L . The HMG-I oncogene causes highly penetrant, aggressive lymphoid malignancy in transgenic mice and is overexpressed in human leukemia. Cancer Res. 2004; 64(10):3371-5. DOI: 10.1158/0008-5472.CAN-04-0044. View